Navigation Links
Pharmasset Announces the Expansion of the ELECTRON Trial in Chronic Hepatitis C
Date:6/8/2011

(HCV) infection. Our research and development efforts are focused on nucleoside/tide analogs, a class of compounds which act as alternative substrates for the viral polymerase, thus inhibiting viral replication. We currently have three clinical-stage product candidates advancing in trials in various populations. Our pyrimidine, PSI-7977, an unpartnered uracil nucleotide analog, is currently under study in three Phase 2b trials in patients with HCV genotypes 1 through 6, including abbreviated duration interferon and interferon-free regimens. Our purine, PSI-938, an unpartnered guanosine nucleotide analog, recently reported safety and efficacy data from 14 days of monotherapy as well as 14 days in combination with the pyrimidine, PSI-7977. An SVR-endpoint study of the purine-pyrimidine combination is anticipated to begin in the third quarter of 2011. Mericitabine (RG7128) continues in two Phase 2b trials and one interferon-free trial being conducted through a strategic collaboration with Roche.

Contact
Richard E. T. Smith, Ph.D.
VP, Investor Relations and Corporate Communications
Office: +1 (609) 865-0693

Forward-Looking Statements

Pharmasset "Safe Harbor" Statement under the Private Securities Litigation Reform Act of 1995: Statements in this press release that are not historical facts are "forward-looking statements," that involve risks, uncertainties, and other important factors, including, without limitation, the risk of cessation or delay of any of the ongoing or planned clinical trials and/or our development of our product candidates, the risk that the results of previously conducted studies involving our product candidates will not be repeated or observed in ongoing or future studies involving our product candidates, the risk that our collaboration with Roche will not continue or will not be successful, and the risk that any one or more of our product candidates will not be successfully developed and com
'/>"/>

SOURCE Pharmasset, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Pharmasset to Present at Two Upcoming Investor Conferences
2. Pharmasset Reports Fiscal Second Quarter 2011 Financial Results
3. Pharmasset Initiates Phase 2b ATOMIC Trial of PSI-7977 for Multiple HCV Genotypes
4. Pharmasset to Webcast an Investor Event From the EASL Meeting
5. Pharmasset to Present at Three Upcoming Investor Conferences
6. Pharmasset to Present at the Leerink Swann Hot Topics Roundtable Conference
7. Pharmasset Reports Fiscal First Quarter 2011 Financial Results
8. Pharmasset Announces Exercise of Underwriters Overallotment Option
9. Pharmasset Prices Public Offering of Common Stock
10. Pharmasset Announces Proposed Public Offering of Common Stock
11. Pharmasset Reports Positive Results from its HCV Clinical Programs
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/29/2014)... , Aug. 29, 2014  United Therapeutics Corporation ... U.S. District Court for the District of ... in the company,s case against Sandoz, Inc. regarding United ... Peter Sheridan ruled that U.S. Patent No. 6,765,117 ... enjoined Sandoz from marketing its generic product until the ...
(Date:8/29/2014)... Aug. 29, 2014 /PRNewswire-iReach/ -- ChemImage will present a ... and New Zealand Forensic Science Society,s 22 nd ... Adelaide, Australia .  Forensic Scientists ... advancements that hyperspectral imaging can bring to examination ... , Director of Product Development at ChemImage, will ...
(Date:8/29/2014)... and MENLO PARK, Calif. , ... Inc. (OTCQB: DMPI) ("DelMar" "the Company") today announced ... statements.  The Company recently changed its fiscal year end ... to list its common stock on a national securities ... financial statements as filed with the United States Securities ...
Breaking Medicine Technology:District Court Decision Received In Remodulin Patent Case 2ChemImage to Discuss Hyperspectral Imaging for Forensic Investigation at the ANZFSS 22nd International Symposium on the Forensic Sciences 2ChemImage to Discuss Hyperspectral Imaging for Forensic Investigation at the ANZFSS 22nd International Symposium on the Forensic Sciences 3DelMar Pharmaceuticals Fiscal 2014 Year End Results and Summary of Recent Developments 2DelMar Pharmaceuticals Fiscal 2014 Year End Results and Summary of Recent Developments 3DelMar Pharmaceuticals Fiscal 2014 Year End Results and Summary of Recent Developments 4DelMar Pharmaceuticals Fiscal 2014 Year End Results and Summary of Recent Developments 5
... 2007 /PRNewswire-FirstCall/ -- Celgene,Corporation announced that the ... its Data Monitoring Committee's (DMC),review of preliminary ... patients with newly diagnosed multiple myeloma has ... of dexamethasone (Decadron) in,combination with lenalidomide suggests ...
... HOUSTON--(BUSINESS WIRE)--Apr 4, 2007 - CytoGenix, Inc. ... an important,pilot study with a novel synDNA(TM) ... protect against the avian (H5N1),influenza virus. The ... mice treated with the Company's synDNA(TM) vaccine,whereas ...
Cached Medicine Technology:ECOG Phase III Newly Diagnosed Multiple Myeloma Trial (E4A03),Reports Lenalidomide Plus Low-Dose Dexamethasone Suggests Survival,Advantage for Patients with Multiple Myeloma 2ECOG Phase III Newly Diagnosed Multiple Myeloma Trial (E4A03),Reports Lenalidomide Plus Low-Dose Dexamethasone Suggests Survival,Advantage for Patients with Multiple Myeloma 3ECOG Phase III Newly Diagnosed Multiple Myeloma Trial (E4A03),Reports Lenalidomide Plus Low-Dose Dexamethasone Suggests Survival,Advantage for Patients with Multiple Myeloma 4ECOG Phase III Newly Diagnosed Multiple Myeloma Trial (E4A03),Reports Lenalidomide Plus Low-Dose Dexamethasone Suggests Survival,Advantage for Patients with Multiple Myeloma 5ECOG Phase III Newly Diagnosed Multiple Myeloma Trial (E4A03),Reports Lenalidomide Plus Low-Dose Dexamethasone Suggests Survival,Advantage for Patients with Multiple Myeloma 6ECOG Phase III Newly Diagnosed Multiple Myeloma Trial (E4A03),Reports Lenalidomide Plus Low-Dose Dexamethasone Suggests Survival,Advantage for Patients with Multiple Myeloma 7CytoGenix Announces Successful Testing of synDNA Vaccine for Avian,Influenza Virus 2
(Date:9/1/2014)... September 01, 2014 The B-cell non-Hodgkin’s ... across six major markets (the US, France, Italy, Germany, ... to $5.41 billion by 2018. , The competitive landscape ... Italy, Germany, Spain and the UK is poised to ... management of the four largest B-cell NHL indications, which ...
(Date:9/1/2014)... Barcelona, Spain Monday 1 September 2014: Daily fruit ... up to 40%, according to research presented at ESC ... The findings from the seven year follow-up study of ... found that the more fruit people ate, the more ... "CVD, including ischaemic heart disease (IHD) and stroke, is ...
(Date:9/1/2014)... As well as having completed the ... pursuing counselor certification in Louisiana. , "I ... training program as well as the Counselor training ... personally and professionally. I am not only dedicated ... to do so. As a Non Violent Crisis ...
(Date:9/1/2014)... 2014 BCC Research ( http://www.bccresearch.com ) ... TECHNOLOGIES AND GLOBAL MARKETS , the global market for ... and is expected to reach $38.7 million in 2014. ... by 2019, which is equivalent to 64.9% compound annual ... transport (RMT) segment is forecasted to grow at a ...
(Date:9/1/2014)... Oakdale, MN (PRWEB) September 01, 2014 In honor ... place on Aug. 22, Animal Emergency & Referral Center of Minnesota ... veterinarian visits a priority for their cats. , Many people don’t ... “it’s too much of a hassle,” but they wouldn’t decide not ... no signs of a cavity. The same goes for pets. Just ...
Breaking Medicine News(10 mins):Health News:B-cell Non-Hodgkin Lymphoma Treatment Market Value worth $5.4 Billion by 2018 Says a New Report Available at MarketOptimizer.org 2Health News:B-cell Non-Hodgkin Lymphoma Treatment Market Value worth $5.4 Billion by 2018 Says a New Report Available at MarketOptimizer.org 3Health News:B-cell Non-Hodgkin Lymphoma Treatment Market Value worth $5.4 Billion by 2018 Says a New Report Available at MarketOptimizer.org 4Health News:Fruit consumption cuts CVD risk by up to 40 percent 2Health News:Fruit consumption cuts CVD risk by up to 40 percent 3Health News:Narconon Louisiana Announces New Certifications For Staff 2Health News:Global Market for Blood-Brain Barrier (BBB) Technology to Reach $471.5 Million in 2019; Highest CAGR Growth in Latin American Market With 10.5% 2Health News:Global Market for Blood-Brain Barrier (BBB) Technology to Reach $471.5 Million in 2019; Highest CAGR Growth in Latin American Market With 10.5% 3Health News:Animal Emergency & Referral Center of Minnesota Celebrates National Take Your Cat to the Vet Day 2Health News:Animal Emergency & Referral Center of Minnesota Celebrates National Take Your Cat to the Vet Day 3
... GAITHERSBURG, Md., Dec. 5 Panacea Pharmaceuticals, ... a fully human sequence,monoclonal antibody against HAAH ... in collaboration with the Massachusetts Institute of ... efficacy in animal,models of cancer. Having a ...
... publication Head and Neck Pathology. Published under the Humana ... North American Society for Head and Neck Pathology (NASHNP). ... December 2007, it will be available free of charge for ... Pathology will present scholarly papers, reviews and case reports that ...
... new ways of tweaking the molecular structure of antibiotics ... fight against powerful super bugs. , The work, led ... geneticist Professor Colin Smith, is published online today (Wednesday ... of the Journal of the American Chemical Society. , ...
... Clinical study compares rotational stability of two differently designed, ... of every day viewing conditions, JACKSONVILLE, Fla., Dec. ... vision may sometimes fluctuate during the day, the answer,may ... new clinical study,demonstrates. The findings, say researchers, may be ...
... Inc., a,medical device company developing endovascular devices for ... announced,the appointment of Christopher R. Barys to the ... to FlowCardia with over 16 years of,experience in ... in the,interventional endovascular products field., Most recently, ...
... Alliance, the leading,management consulting firm specializing in the ... Vice President,of the firm,s Business Development practice, will ... at the Strategic Research,Institute,s (SRI) Pharma & Biotech ... on December 10-11, 2007, at the San Diego ...
Cached Medicine News:Health News:Panacea Pharmaceuticals Announces Selection of PAN-622 - A Fully Human Sequence Monoclonal Antibody Against HAAH - As Its Lead Cancer Therapeutic Product 2Health News:Panacea Pharmaceuticals Announces Selection of PAN-622 - A Fully Human Sequence Monoclonal Antibody Against HAAH - As Its Lead Cancer Therapeutic Product 3Health News:Panacea Pharmaceuticals Announces Selection of PAN-622 - A Fully Human Sequence Monoclonal Antibody Against HAAH - As Its Lead Cancer Therapeutic Product 4Health News:Scientists strike blow in superbugs struggle 2Health News:Contact Lens Shift Can Compromise Vision of People with Astigmatism with the Blink of an Eye 2Health News:Contact Lens Shift Can Compromise Vision of People with Astigmatism with the Blink of an Eye 3Health News:Contact Lens Shift Can Compromise Vision of People with Astigmatism with the Blink of an Eye 4Health News:Contact Lens Shift Can Compromise Vision of People with Astigmatism with the Blink of an Eye 5Health News:FlowCardia, Inc. Appoints Chris Barys Senior VP, Sales 2Health News:Campbell Alliance Business Development Practice Leader to Co-Chair and Keynote at SRI Pharma Licensing Summit 2Health News:Campbell Alliance Business Development Practice Leader to Co-Chair and Keynote at SRI Pharma Licensing Summit 3
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
Medicine Products: